|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||EMA/FDA review||Commercial Rights|
|eryaspase (GRASPA® (1))||Asparaginase||Pancreatic Cancer|
Pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. We believe pancreatic cancer is a suitable indication for eryaspase because it involves a large proportion of tumors that are believed to be sensitive to L-asparaginase depletion, allowing our product candidate to potentially have an impact.
A phase 2b study showed positive results on 140 patients suffering from metastatic pancreatic cancer in second line.